This document is scheduled to be published in the Federal Register on 09/20/2018 and available online at https://federalregister.gov/d/2018-20423, and on govinfo.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby

given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions

could disclose confidential trade secrets or commercial property such as patentable material, and

personal information concerning individuals associated with the grant applications, the

disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33

Clinical Trial Optional)

Date: October 3, 2018

Time: 12:00 PM to 4:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

1

Contact Person: Ipolia R. Ramadan, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Exploring Epigenomic or Non-Coding RNA Regulation in the

Development, Maintenance, or Treatment of Chronic Pain (R61/R33

Clinical Trial Optional)

Date: October 12, 2018

Time: 12:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Ipolia R. Ramadan, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity

Initiative (U24 - Clinical Trial Not Allowed)

Date: October 17, 2018

Time: 2:00 PM to 4:30 PM

Agenda: To review and evaluate cooperative agreement applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction

Research Programs, National Institutes of Health, HHS)

Dated: September 14, 2018.

Natasha M. Copeland,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2018-20423 Filed: 9/19/2018 8:45 am; Publication Date: 9/20/2018]